This is an important milestone in the strategic development of Adistem’s technology platform
Melbourne, Australia (PRWEB) July 12, 2011
The Directors of Adistem Limited (Hong Kong) were delighted to hear that they were granted formal ethics approval for a clinical trial on knee osteoarthritis using their proprietary Activated Platelet Rich Plasma (PRP) Technology.
The study is titled “Intra-articular injection of platelet-rich plasma in patients with knee osteoarthritis: A randomized controlled trial,” and will enroll approximately 30 patients presenting with mild to moderate knee joint osteoarthritis.
The Principal Investigators are Dr Kade Paterson from the Australian Catholic University (Melbourne) and Dr Dan Bates from the Lakeside Sports Medicine Centre (Melbourne). The study is being carried out at the Lakeside Sports Medicine Centre (Melbourne, Victoria Australia).
The Australian Catholic University Research Ethics Committee has reviewed this study and has given approval to conduct this research. This study conforms to the principles set out by the National Statement on Ethical Conduct in research involving humans and according to Good Clinical Practice Guidelines
“The approval and commencement of this clinical trial for osteoarthritis is an important milestone in the strategic development of Adistem’s technology platform,” said CEO, Dr. Nick Ede. He continued, “This formal clinical trial will add to our on-going clinical trials in the EU and Asia, escalating Adistem’s impressive track record of product development, commercialization and clinical applications in the cellular therapy field.”
“The Company is at an exciting stage, largely due to its expanding clinical trial initiatives, now with 3 major clinical trials underway, one for Idiopathic Pulmonary Fibrosis and another for Autism Spectral disorder”, said Mr. James Thornton and Dr Vasilis Paspaliaris, founding Directors, Adistem Ltd.
Adistem discovers and develops new technologies and methods to help clinicians use autologous adult stem cells to address degenerative disease conditions – and to assist in certain cosmetic and plastic surgery procedures. Clinicians in 26 different countries are currently using Adistem’s stem cell technology. Specifically Adistem is developing several peptide therapeutics against a number of chronic disease targets including HIV, pain and Type II Diabetes.
For more information: visit http://www.adistem.com/trial-osteoarthritis.htm
Dr Nicholas Ede